NDAORALCAPSULE, EXTENDED RELEASE
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
CODIMAL-L.A. 12 (chlorpheniramine maleate; pseudoephedrine hydrochloride) by Ascentage Pharma. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CODIMAL-L.A. 12 is an extended-release oral capsule combining chlorpheniramine maleate (antihistamine) and pseudoephedrine hydrochloride (nasal decongestant) for symptomatic relief of upper respiratory allergies including hay fever, runny nose, itching, watery eyes, and throat irritation. The product is in pre-launch stage under NDA review by Ascentage Pharma.
Pre-Launch
Pre-launch products require intensive cross-functional team deployment for regulatory, commercial, and medical readiness; significant hiring anticipated in brand management, field sales, and medical affairs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CODIMAL-L.A. 12 at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.